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Studies on red blood cell (RBC) antibodies in Africa routinely use standard test cells from donors of 
Caucasian descent. There are no systematic data on alloimmunization against antigens that are almost 
exclusively present in Africans. We studied the prevalence of antibodies in transfused Ghanaian 
patients with sickle cell disease (SCD) using standard test cells (representing predominantly antigens 
more common in Caucasians (Caucasian antigens) and cells expressing antigens more common 
among Africans (African antigens). Antibodies were present in 16% of 221 patients; 31% of these 
were directed against African antigens that were not detected with standard test cells. Our findings are 
not only relevant for an African setting, but also for Western blood banks that are developing 
strategies to recruit more African donors. 
 
Transfusions in patients with SCD are associated with high rates of RBC alloimmunization 
against multiple antigens. Alloantibody screening is performed with standard reagent test cells, mostly 
from donors of Caucasian descent that lack antigens that are more prevalent in Africans. 
Alloimmunisation involving antigens that are almost exclusively present in Africans has not been 
studied systematically in a setting where both patients and donors are Africans. We determined the 
prevalence of RBC antibodies against Caucasian and African antigens in multi-transfused patients 
with SCD in Ghana, where pre-transfusion antibody screening and indirect antiglobulin crossmatch 
are not routine. 
Our cross-sectional study recruited patients between July and December 2018, from two 
tertiary hospitals. Patients were eligible for inclusion if they were at least two years of age and had 
received at least two transfusions at least 6 weeks before study enrolment (to allow time to develop 
antibodies). Patients were episodically transfused with non-leucoreduced whole blood from African 
donors. Donors were not screened for sickle cells. Participants’ demographics and transfusion history 
were retrieved from hospital files. Patients or caretakers provided this information, if missing from 
hospital files, using a standard questionnaire.  
Plasma and buffy coat samples, taken at enrolment, were frozen at –80oC and transported to 
Sanquin, Amsterdam, The Netherlands, for routine antibody testing against a standard three-cell 
reagent panel (Bio-Rad Laboratories AG, Cressier, Switzerland), not expressing antigens that are 
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more common in Africans, using a low ionic strength solution (LISS) indirect anti-globulin gel 
column agglutination test. Using the same method, antibody identification was performed with 
commercial panels of reagent RBC of selected phenotypes and against eight selected cells with 
antigens that are very rare (<0.01% to 1%) in Caucasians but more frequent (0.5% to 32%) in 
Africans (i.e. MNS6 (He), MNS25 (Dantu), RH10 (V), RH20 (VS), RH30 (Goa), RH32, RH43 
(Crawford) and KEL6 (Jsa)).1 These antigens were selected based on the availability of RBC 
expressing rare antigens archived in the Immunohaematology Diagnostics laboratory at Sanquin. 
Antibody specificities were confirmed by re-testing with two RBC expressing and two RBC not 
expressing the target antigens. For patients with anti-D, RHD genotyping was done on genomic DNA 
by Multiplex Ligation-dependent Probe Amplification (MLPA) assay according to the manufacturers’ 
protocol (MRC Holland, Amsterdam, the Netherlands) using a thermocycler (Veriti, Applied 
Biosystems, Nieuwerkerk aan de IJssel, the Netherlands).2 When MLPA results were equivocal, DNA 
sequencing was performed to determine the RHD genotype. Sequence products were analyzed on a 
genetic analyzer (3730xl, Applied Biosystems). 
The study was approved by the Committee on Human Research, Publication and Ethics, 
Kwame Nkrumah University of Science and Technology, and Korle Bu Teaching Hospital and 
Liverpool School of Tropical Medicine Institutional Review Boards. Patients or their caretakers gave 
written informed consent to participate in the study.  
Statistical analyses were performed using the SPSS (IBM Corp., Armonk, NY, USA). Results 
for continuous variables were presented as medians (range) and categorical variables as frequencies 
(percentages).  
 
We recruited 221 Ghanaian patients (123 women and 98 men; 89% HbSS, 10% HbSC, one 
HbSD and one HbSβ0-thalassemia). The median age at enrolment was 17 years (range 2-66 years). 
Patients had received a median of three (range 2-40) whole blood transfusions and the median period 
between last transfusion and study enrolment was 2.1 years (range 6 weeks-55.5 years).  
Antibody screening, using standard test cells, was positive in 24 patients (10.9%) and 
revealed 25 antibody specificities (table 1). Although D antigen matching was routine in Ghana, anti-
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D was present in seven patients. RHD genotyping of these patients revealed that three women and two 
men had only RHD-null alleles (three RHD*01N.01/RHD*01N.01, one RHD*01N.01/RHD*01N.03 
and one RHD*08N.01/RHD*08N.01). In the three D- women, anti-D could have been induced by a 
D+ pregnancy. For the two D- men, errors in blood group typing or mistakenly transfusing patients 
with D+ blood are possible causes for the anti-D. The presence of RH variants expressing weak D 
among D negative African donors might have contributed to these mismatched transfusions. Two 
patients possessed variant RHD genes (RHD*03.04 and RHD*04.01) associated with D+ serology and 
carriers of these variants can make anti-D after D-antigen exposure.3,4 
The nine patients with D, G and s antibodies and the three patients with pan-reactive 
antibodies, were not tested against the African antigens because African test cells lacking these 
antigens were not available. Of the remaining 209 patients, eleven (5.3%)  patients who did not have 
alloantibodies against the standard three-cell screen panel, had  a total of eleven antibodies against 
African antigens; 3 anti-Dantu (for one, confirmation by a second Dantu+ test cell was not performed, 
due to lack of Dantu+ cells), 2 anti-He, 2 anti-V/VS, 1 anti-VS, 1 anti-RH32, 1 anti-Goa and 1 
antibody probably against a low frequency antigen but no plasma was available for further 
investigation (Table 1). 
Overall, 31.4% of alloimmunized patients had antibodies against African antigens that were 
not detected during standard antibody screening. Other studies in patients with SCD have reported 
antibodies against African antigens5-13 but these patients were transfused in the US and Europe and 
thus not exclusively with blood from African donors. Furthermore, these antibodies were encountered 
during complex antibody workup, crossmatch incompatibilities and hemolytic transfusion reactions 
rather than through systematic screening. The antibody frequency against African antigens in these 
studies ranged from 0.7% to 13.3%, with anti-V/VS, anti-Jsa and anti-Goa representing 90% of 
specificities. So far, only one study in France systematically screened a heavily transfused patient 
cohort with SCD using selected African red cells. After receiving a mean of 144 RBC transfusions 
(11.5% from donors of African descent) 5.2% of 211 patients had antibodies against African-specific 
antigens (MNS6, RH10, RH20, RH23, RH30 and KEL6).14 However, unlike our study, these patients 
received blood matched for major Rh and K antigens, which precludes insight in differences in 
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immunogenicity of African and the classical ‘major’ blood group antigens. Surprisingly, in our study 
7 out of 36 (19%) antibodies were against low frequency African antigens (i.e. Goa 2%, RH32 1%, He 
1% and Dantu 0.5% in Africans).1 This suggests that these antigens are immunogenic in Ghanaians 
and may be more immunogenic than antigens for which we test in the European setting. The results 
from these studies stress the importance of testing against African antigens when patients receive 
transfusions from African donors.  
Antibodies in patients with SCD are notorious for their high evanescence rate, which may be 
up to 60-80%.15 Because our study had a cross-sectional design, it is likely that antibody frequency 
was underestimated. In the French study, none of the eight previously detected African antibodies, 
were detectable at study enrollment, suggesting that African antibodies also have a high evanescence 
rate.14 Furthermore, African antibodies have been implicated in severe hemolytic transfusion reactions 
upon receipt of transfusions with the cognate antigens.12 
Our study was limited by the scarcity of test cells expressing African antigens, so antibodies 
against other African antigens, such as RH49 (STEM), GE6 (Lsa) and CROM3 (Tcb), might have been 
missed.1 Furthermore, antibodies against antigens that are more frequently expressed on RBC of 
Ghanaian donors might have been missed, because we did not specifically test Ghanaian RBC. 
Since we found African antibodies in African patients transfused with African blood, it is also 
quite likely that similar antibodies may be elicited in Caucasian patients receiving blood from African 
donors and through pregnancy. These antibodies cannot be detected during pre-transfusion antibody 
screening using standard test cells and without performing an indirect antiglobulin crossmatch with 
donor cells (and many countries only perform type and screen). Our findings are relevant for blood 
banks in Western countries since many are developing strategies to recruit more African donors. 
Unless they can supply antigen compatible blood, African antibodies may increasingly be missed as 
the pool of African donors expands. 
This is the first study to systematically screen for RBC antibodies against African antigens in 
a large cohort of transfused patients with SCD who were exclusively transfused with blood from 
African donors. To increase the availability of test cells with African antigens, African donors should 
be typed, for relevant antigens and then retain them as repeat donors for the preparation of test cells.  
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As long as antigens commonly expressed in Africans are not incorporated on the RBC testing panel, 
transfusions for patients with SCD should be cross-matched using an indirect antiglobulin test, even 
when they do not have RBC antibodies using the standard three-cell screen panel. 
For original data, please contact lilian.boateng@lstmed.ac.uk 
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Table 1. Specificities of the 36 red blood cell antibodies in the 35 alloimmunized multi-transfused 
Ghanaian patients with sickle cell disease. 
Blood group 
system 
Antibody specificity, (n) 
Panel expressing antigens more 
common in Caucasians 
African panel expressing antigens 
more common in Africans 
Rh E (10); D (7); G (2) V/VS (2); VS (1); Goa (1); RH32 (1) 
Kell K (1)  
MNS s (1) Dantu (3); He (2) 
Unidentified Pan-reactive (3); Non-specified* (1) Non-specified* (1) 
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